Biomarkers for Systemic Therapy in Metastatic Breast Cancer
Key Points
Key Points
Testing for ESR1, PIK3CA, AKT1 and inactivation of PTEN somatic variants and germline BReast CAncer gene 1 (BRCA1), BReast CAncer gene 2 (BRCA2), and partner and localizer of BRCA2 (PALB2) pathogenic variants (mutations) to guide therapy.
Testing tumors for homologous recombination deficiency, expression of programmed cell death ligand-1 (PD-L1), deficient mismatch repair microsatellite instability (dMMR/MSI), tumor mutational burden (TMB), neurotrophic tyrosine receptor kinase (NTRK) gene fusions, and trophoblast cell-surface antigen 2 (TROP2) expression to determine eligibility for selected treatments.
The use of cell-free, circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) for monitoring treatment response.
Treatment
...eatment...
...ations from 2024 Rapid Recommendation Updat...
...1.1The Expert Panel recommends multiple lines...
...commendation 1.2There are no comparative efficac...
...ent Options According to Prior Endocrine Ther...
...ommendations from 2023 Rapid Recommend...
...treatment selection, the Expert Panel recommends...
...atients previously treated with ET a...
...s from 2022 Focused Guideline Update...
...ation 1.1Patients with locally recurrent...
...ion 3.1Patients with metastatic HER2-...
...mmendation 3.2There is insufficient evidence t...
...n 4.1There are insufficient data at presen...
Recommendation 5.1Patients with local...
...n 6.1Patients with metastatic cancer...
....1Patients with metastatic cancer who...
...ion 8.1Clinicians may test for NTRK fusions...
Recommendation 9.1There are insufficient data t...
...ommendation 10.1There are insufficient...
...ion 11.1There are insufficient data...
...ons Unchanged From 2015 Guideline...
...itial presentation of metastasis from breast can...
...commendation for Tissue Biomarkers...
...ts who are already receiving systemic t...
...dations for Circulating Tumor Markers...
...s already receiving systemic therapy...
...nic antigen (CEA), cancer antigen (CA) 15-3,...
...de to ASCO Biomarker Testing in Metastatic Breas...
...ts Recommended by the ASCO Expert P...
...Tests Not Recommended by the ASCO Expert Pane...
...2. At-A-Glance Guide to ASCO Biomarke...
...A-Glance Guide to ASCO Biomarker Testing in Me...
...eves that cancer clinical trials are...